President Maia Sandu is considering the possibility for the Moldovans toalso benefit from the “Johnson & Johnson” vaccine either through the COVAX Facility or directly. The subject was discussed by President Sandu with representatives of “Janssen Pharmaceutica”, which is owned by “Johnson & Johnson”, IPN reports.
“I told them about the pandemic situation in the Republic of Moldova and about the efforts made to supply the country with vaccines. We explored the possibility for our country to also benefit from this preparation either through the COVAX Facility or directly,” stated Maia Sandu.
According to the presidential press service, the COVID-19 vaccine produced by this company was approved and is used in the U.S. Several days ago, it was also approved by the European Medicines Agency and was homologated by the Word Health Organization.
Maia Sandu assured that together with the presidential team, she will continue to discuss with Moldova’s partners and producer companies so as to ensure the Moldovans’ access to different COVID-19 vaccines.
- 2% of Moldova’s population vaccinated against COVID-19 by now
- Lawyer: MPs and inspectors acted abusively when they blocked activity of Micăuți Quarry
- Vaccination with second dose of Pfizer vaccine underway
- Peter Michalko about intention to take money from reserves: This is attack on NBM’s independence
- Official exchange rate for date 13.04.2021